United States-based BioStem Technologies Inc, a global life sciences corporation, has chosen United States-based ProcessPro's Global ERP solution to streamline and optimise its biopharmaceutical manufacturing, API repackaging and pharmaceutical reformulation operations, it was reported yesterday.
BioStem Technologies says that its decision to collaborate with ProcessPro was driven by a desire to consolidate business processes into one centralised, real-time ERP solution. ProcessPro Global intends to assist with the certification and compliance needs of FDA regulations with full forward and backward lot traceability and robust reporting.
Joe Blauert, ProcessPro general manager, said, 'BioStem Technologies has solidified their commitment to growth and success with their choice of ProcessPro Global. The pharmaceutical industry is highly regulated, and BioStem Technologies will stay competitive by utilising our fully adaptable and scalable solution.'
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data